Biocon secures 10-year pertuzumab supply partnership in Brazil
Biocon has secured a 10-year pertuzumab supply partnership in Brazil under the country's Productive Development Partnership programme.
Biocon, Bahiafarma and Bionovis received full allocation for pertuzumab supply, supporting long-term access to the HER2-targeted breast cancer therapy in the Brazilian market.
Biocon is eligible for milestone payments and a share of programme revenues, making the agreement a significant long-term commercial partnership for its oncology biosimilars business.
Field | Content |
Alert Type | Long-term supply partnership |
Company | Biocon |
Partners | Bahiafarma and Bionovis |
Product | Pertuzumab |
Therapy Area(s) | Oncology |
Indication | HER2-positive breast cancer |
Geography | Brazil |
Agreement Duration | 10 years |
Programme | Productive Development Partnership |
What Happened | Biocon and its Brazilian partners received full allocation under a 10-year programme for the supply of pertuzumab. |
Why It Matters | The agreement provides Biocon with a long-term commercial position in Brazil's oncology market and supports access to a major HER2-targeted therapy. |
Supporting Context | Biocon is eligible for milestone payments and a share of programme revenues under the arrangement. |
Key Takeaway | The 10-year pertuzumab partnership strengthens Biocon's oncology biosimilars footprint in Brazil. |
What to Watch | Technology transfer, supply execution and milestone payments under the programme. |
Primary Source | Biocon |
Relevant Date | September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios